Good News for Smoldering Myeloma: Decades of Data Show Better Survival | EHA 2026

New data presented by Malin Hultcrantz at EHA 2026 analyzed outcomes from the Swedish national registry to better understand survival trends in smoldering multiple myeloma (SMM). This large population-based study shows how advances in monitoring, risk assessment, and treatment have improved outcomes for patients diagnosed with smoldering myeloma over time. If this video has helped you or a loved one, consider donating to HealthTree. Every donation helps us continue to create free and high-quality blood cancer educational content: https://give.healthtree.org/give/6286... For an organized lesson structure, watch on our site here: https://linktr.ee/HealthTreeUniversity Create a free account to track your progress, bookmark lessons, and keep up-to-date on the latest advancements in treating cancer! Patients have the key to find cures for cancer. Learn more about HealthTree's services here: https://healthtree.org/curehub?utm_so... Educated and empowered patients have better outcomes. We've partnered with hundreds of medical experts and doctors to help you learn more about your disease.

The Immune System in Myeloma: How It Shapes Treatment and Outcomes
▶︎

The Immune System in Myeloma: How It Shapes Treatment and Outcomes

CAR-T Without the Wait: Reprogramming T-cells Inside Your Body for Myeloma | EHA 2026
▶︎

CAR-T Without the Wait: Reprogramming T-cells Inside Your Body for Myeloma | EHA 2026

DocTalk Podcast: You Have a Cancer Diagnosis, Now What?
▶︎

DocTalk Podcast: You Have a Cancer Diagnosis, Now What?

Real-World Treatment Sequencing After CAR-T vs Bispecific Antibodies in Multiple Myeloma | EHA 2026
▶︎

Real-World Treatment Sequencing After CAR-T vs Bispecific Antibodies in Multiple Myeloma | EHA 2026

Optimizing Bispecific Therapy in Myeloma: Choosing the Right Time for Treatment | EHA 2026
▶︎

Optimizing Bispecific Therapy in Myeloma: Choosing the Right Time for Treatment | EHA 2026

Recent Advances in Multiple Myeloma with Dr. Dan Vogl
▶︎

Recent Advances in Multiple Myeloma with Dr. Dan Vogl

She’s 12. She Sings Aretha Franklin… Until Simon TELLS Her to Do It Acapella! 😳
▶︎

She’s 12. She Sings Aretha Franklin… Until Simon TELLS Her to Do It Acapella! 😳

Researching Links Between Diet + Multiple Myeloma w/ Dr  Urvi Shah, MD
▶︎

Researching Links Between Diet + Multiple Myeloma w/ Dr Urvi Shah, MD

Myeloma 101: Understanding Multiple Myeloma, Risk Factors, Diagnosis & Treatments Explained
▶︎

Myeloma 101: Understanding Multiple Myeloma, Risk Factors, Diagnosis & Treatments Explained

Beyond One-Size-Fits-All: Martin Kaiser on Precision Diagnostics in Multiple Myeloma | EHA 2026
▶︎

Beyond One-Size-Fits-All: Martin Kaiser on Precision Diagnostics in Multiple Myeloma | EHA 2026

What Happens After CAR T-Cell Therapy? Myeloma Experts Answer Common Questions
▶︎

What Happens After CAR T-Cell Therapy? Myeloma Experts Answer Common Questions

Talquetamab Steps Forward: MonumenTAL-3 - A New Potential for GPRC5D Therapy in Myeloma | EHA 2026
▶︎

Talquetamab Steps Forward: MonumenTAL-3 - A New Potential for GPRC5D Therapy in Myeloma | EHA 2026

Is Multiple Myeloma Fatal? What Experts Say About Living a Normal Life
▶︎

Is Multiple Myeloma Fatal? What Experts Say About Living a Normal Life

Colin Farrell Opens Up About His Son With Angelman Syndrome | PEOPLE
▶︎

Colin Farrell Opens Up About His Son With Angelman Syndrome | PEOPLE

I Used 100% CASTOR OIL Eye Drops for 30 days - Here's What happened
▶︎

I Used 100% CASTOR OIL Eye Drops for 30 days - Here's What happened

Can We Prevent Taste Loss with Talquetamab? TALISMAN Study Brings New Hope | EHA 2026
▶︎

Can We Prevent Taste Loss with Talquetamab? TALISMAN Study Brings New Hope | EHA 2026

DREAMM-9 Final Analysis: Blenrep + VRd Shows Lasting Benefit in Newly Diagnosed Myeloma | EHA 2026
▶︎

DREAMM-9 Final Analysis: Blenrep + VRd Shows Lasting Benefit in Newly Diagnosed Myeloma | EHA 2026

Next Generation of CAR-T: AZD0120 Dual BCMA/CD19 CAR-T w/ Rapid Manufacturing for Myeloma | EHA 2026
▶︎

Next Generation of CAR-T: AZD0120 Dual BCMA/CD19 CAR-T w/ Rapid Manufacturing for Myeloma | EHA 2026

Myeloma Treatment Debates: Key CoMy 2026 Controversies and Clinical Decisions with Mohamad Mohty
▶︎

Myeloma Treatment Debates: Key CoMy 2026 Controversies and Clinical Decisions with Mohamad Mohty

Beyond MRD Negative: FORTE Trial Reveals Why Staying MRD Negative Matters in Myeloma | ASCO 2026
▶︎

Beyond MRD Negative: FORTE Trial Reveals Why Staying MRD Negative Matters in Myeloma | ASCO 2026